Search All Tech Briefings

Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available. Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 21 Results

Clear All Filters

Title	Intervention	Indication	Therapeutic Area	Year	Actions
Isatuximab in addition to bortezomib, lenalidomide and dexamethasone for newly diagnosed transplant-ineligible multiple myeloma – first line	Bortezomib (Velcade; bortezomib mannitol boronic ester) , Dexamethasone (dexamethasone sodium metasulfobenzoate) , Isatuximab (SAR650984; Sarclisa) , Lenalidomide (Revlimid)	Multiple myeloma (MM)	Haematological Cancer and Lymphomas	2021	View \| Download
Isatuximab in addition to carfilzomib and dexamethasone for relapsed and/or refractory multiple myeloma	Carfilzomib (Kyprolis; ONO-7057) , Dexamethasone (dexamethasone sodium metasulfobenzoate) , Isatuximab (SAR650984; Sarclisa)	Multiple myeloma (MM)	Haematological Cancer and Lymphomas	2019	View \| Download
Isatuximab in Addition to Pomalidomide and Dexamethasone for Relapsed and/or Refractory Multiple Myeloma	Dexamethasone (dexamethasone sodium metasulfobenzoate) , Isatuximab (SAR650984; Sarclisa) , Pomalidomide (Imnovid; CC-4047; Pomalyst)	Multiple myeloma (MM)	Haematological Cancer and Lymphomas	2018	View \| Download
Isatuximab induction therapy with bortezomib, lenalidomide and dexamethasone for previously untreated multiple myeloma	Bortezomib (Velcade; bortezomib mannitol boronic ester) , Dexamethasone (dexamethasone sodium metasulfobenzoate) , Isatuximab (SAR650984; Sarclisa) , Lenalidomide (Revlimid)	Multiple myeloma (MM)	Haematological Cancer and Lymphomas	2023	View \| Download
Melphalan flufenamide in combination with dexamethasone for treating adult patients with relapsed or refractory multiple myeloma	Dexamethasone (dexamethasone sodium metasulfobenzoate) , Melphalan flufenamide hydrochloride (Ygalo; Mel-flufen; J-1)	Multiple myeloma (MM)	Haematological Cancer and Lymphomas	2020	View \| Download
Pomalidomide (Imnovid) with bortezomib and dexamethasone for relapsed or refractory multiple myeloma‐ second line and beyond	Bortezomib (Velcade; bortezomib mannitol boronic ester) , Dexamethasone (dexamethasone sodium metasulfobenzoate) , Pomalidomide (Imnovid; CC-4047; Pomalyst)	Multiple myeloma (MM)	Haematological Cancer and Lymphomas	2017	View \| Download
Selinexor in addition to bortezomib and low-dose dexamethasone for relapsed or refractory multiple myeloma	Bortezomib (Velcade; bortezomib mannitol boronic ester) , Dexamethasone (dexamethasone sodium metasulfobenzoate) , Selinexor (KPT-330; Xpovio)	Multiple myeloma (MM)	Haematological Cancer and Lymphomas	2020	View \| Download
Selinexor in combination with low-dose dexamethasone for penta-refractory multiple myeloma	Dexamethasone (dexamethasone sodium metasulfobenzoate) , Selinexor (KPT-330; Xpovio)	Multiple myeloma (MM)	Haematological Cancer and Lymphomas	2018	View \| Download
Subcutaneous isatuximab with pomalidomide and dexamethasone for treating relapsed and/or refractory multiple myeloma	Dexamethasone (dexamethasone sodium metasulfobenzoate) , Pomalidomide (Imnovid; CC-4047; Pomalyst) , Subcutaneous isatuximab	Multiple myeloma (MM)	Haematological Cancer and Lymphomas	2023	View \| Download
Venetoclax in combination with bortezomib and dexamethasone for relapsed multiple myeloma - second line and beyond	Bortezomib (Velcade; bortezomib mannitol boronic ester) , Dexamethasone (dexamethasone sodium metasulfobenzoate) , Venetoclax (Venclyxto; ABT-199; Venclexta; GDC-0199)	Multiple myeloma (MM)	Haematological Cancer and Lymphomas	2018	View \| Download